Park Bokyung, Yoo Keon Hee, Kim Changsung
Department of Bioscience and Biotechnology, Sejong University, Korea.
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea.; Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Korea.
Blood Res. 2015 Dec;50(4):194-203. doi: 10.5045/br.2015.50.4.194. Epub 2015 Dec 21.
Hematopoietic stem cell transplantation (HSCT) is the first field where human stem cell therapy was successful. Flooding interest on human stem cell therapy to cure previously incurable diseases is largely indebted to HSCT success. Allogeneic HSCT has been an important modality to cure various diseases including hematologic malignancies, various non-malignant hematologic diseases, primary immunodeficiency diseases, and inborn errors of metabolism, while autologous HSCT is generally performed to rescue bone marrow aplasia following high-dose chemotherapy for solid tumors or multiple myeloma. Recently, HSCs are also spotlighted in the field of regenerative medicine for the amelioration of symptoms caused by neurodegenerative diseases, heart diseases, and others. Although the demand for HSCs has been growing, their supply often fails to meet the demand of the patients needing transplant due to a lack of histocompatible donors or a limited cell number. This review focuses on the generation and large-scale expansion of HSCs, which might overcome current limitations in the application of HSCs for clinical use. Furthermore, current proof of concept to replenish hematological homeostasis from non-hematological origin will be covered.
造血干细胞移植（HSCT）是人类干细胞治疗取得成功的首个领域。对人类干细胞治疗以治愈先前无法治愈疾病的浓厚兴趣在很大程度上归功于HSCT的成功。异基因HSCT一直是治疗各种疾病的重要方式，包括血液系统恶性肿瘤、各种非恶性血液系统疾病、原发性免疫缺陷疾病和先天性代谢缺陷，而自体HSCT通常用于在实体瘤或多发性骨髓瘤的高剂量化疗后挽救骨髓再生障碍。最近，造血干细胞在再生医学领域也备受关注，用于改善由神经退行性疾病、心脏病等引起的症状。尽管对造血干细胞的需求一直在增长，但由于缺乏组织相容性供体或细胞数量有限，其供应往往无法满足需要移植患者的需求。本综述重点关注造血干细胞的产生和大规模扩增，这可能克服目前造血干细胞临床应用中的局限性。此外，还将涵盖目前从非血液来源补充血液稳态的概念验证。
